Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea

Completed · Phase 4

Conditions studied: Rosacea

In brief

This study will evaluate the safety and tolerability of oxymetazoline HCl cream 1.0% when used as an adjunctive treatment to energy-based therapy for participants with moderate to severe persistent facial erythema associated with rosacea.

Key facts

Study ID
NCT03380390
Run by
Aclaris Therapeutics, Inc.
People needed
46
Starts
2017-12-04
Expected to finish
2018-06-15
Last updated by the study team
2019-09-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.